Sep 12, 2023 / 12:50PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Great. Good morning, everybody. Thanks for joining us. I'm Terence Flynn, the U.S. Pharma & Biotech analyst here at Morgan Stanley. We're very pleased to be hosting Amgen. Today, from the company, we have Bob Bradway, who is the company's Chairman and CEO.
Before we get started for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Bob, before you launch into my questions, I'll turn it over to you for some opening remarks, but thanks so much for your time today.
Robert A. Bradway - Amgen Inc. - Chairman, CEO & President
Thank you, Terence. Thanks for having us, and thank you all for joining us. Perhaps, before we get started, I might just say a word or 2 about Horizon. I know Terence probably won't be in a position
Amgen Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers